Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Lock

Showing results (131-140 of 220) with videos related to

Pageof 22
Sort By:
Pediatric Blood & Cancer|December 18, 2009
Initial testing of topotecan by the pediatric preclinical testing programHernan Carol, Peter J Houghton, Christopher L Morton, et al.
Oncotarget|September 14, 2016
Heterogeneity in mechanisms of emergent resistance in pediatric T-cell acute lymphoblastic leukemiaBabasaheb D Yadav, Amy L Samuels, Julia E Wells, et al.
Pediatric Blood & Cancer|August 27, 2010
Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing programHernan Carol, Christopher L Morton, Richard Gorlick, et al.
Leukemia|December 12, 2012
FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradationA Malyukova, S Brown, R Papa, et al.
Pediatric Blood & Cancer|November 20, 2014
Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing programE Anders Kolb, Richard Gorlick, Stephen T Keir, et al.
Oncogene|August 3, 2010
A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patientsS H Oram, J A I Thoms, C Pridans, et al.
Blood|February 7, 2004
Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapiesNatalia L M Liem, Rachael A Papa, Christopher G Milross, et al.
Pediatric Blood & Cancer|May 18, 2011
Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing programRichard B Lock, Hernan Carol, Christopher L Morton, et al.
Pediatric Blood & Cancer|January 11, 2013
Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing ProgramRichard B Lock, Hernan Carol, John M Maris, et al.
Pediatric Blood & Cancer|March 26, 2014
Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing programHernan Carol, John M Maris, Min H Kang, et al.
Pageof 22

Showing results (131-140 of 220) with videos related to

Sort By:
Pageof 22
Pediatric Blood & Cancer|December 18, 2009
Initial testing of topotecan by the pediatric preclinical testing programHernan Carol, Peter J Houghton, Christopher L Morton, et al.
Oncotarget|September 14, 2016
Heterogeneity in mechanisms of emergent resistance in pediatric T-cell acute lymphoblastic leukemiaBabasaheb D Yadav, Amy L Samuels, Julia E Wells, et al.
Pediatric Blood & Cancer|August 27, 2010
Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing programHernan Carol, Christopher L Morton, Richard Gorlick, et al.
Leukemia|December 12, 2012
FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradationA Malyukova, S Brown, R Papa, et al.
Pediatric Blood & Cancer|November 20, 2014
Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing programE Anders Kolb, Richard Gorlick, Stephen T Keir, et al.
Oncogene|August 3, 2010
A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patientsS H Oram, J A I Thoms, C Pridans, et al.
Blood|February 7, 2004
Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapiesNatalia L M Liem, Rachael A Papa, Christopher G Milross, et al.
Pediatric Blood & Cancer|May 18, 2011
Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing programRichard B Lock, Hernan Carol, Christopher L Morton, et al.
Pediatric Blood & Cancer|January 11, 2013
Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing ProgramRichard B Lock, Hernan Carol, John M Maris, et al.
Pediatric Blood & Cancer|March 26, 2014
Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing programHernan Carol, John M Maris, Min H Kang, et al.
Pageof 22